-
EP3710002
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3710002
| EP3710002 - DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 17.03.2023 Database last updated on 08.04.2026 | |
| Former | Request for examination was made Status updated on 21.08.2020 | ||
| Former | The international publication has been made Status updated on 28.05.2019 | Most recent event Tooltip | 23.01.2026 | Change - applicant | published on 25.02.2026 [2026/09] | Applicant(s) | For all designated states C4 Therapeutics, Inc. 490 Arsenal Way, Suite 120 Watertown, MA 02472 / US | [2026/09] |
| Former [2020/39] | For all designated states C4 Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown, MA 02472 / US | Inventor(s) | 01 /
PHILLIPS, Andrew, J. c/o C4 Therapeutics Inc. 490 Arsenal Way Suite 200 Watertown MA 02472 / US | 02 /
NASVESCHUK, Christopher, G. c/o C4 Therapeutics Inc. 490 Arsenal Way Suite 200 Watertown MA 02472 / US | 03 /
HENDERSON, James, A. c/o C4 Therapeutics Inc. 490 Arsenal Way Suite 200 Watertown MA 02472 / US | 04 /
HE, Minsheng c/o C4 Therapeutics Inc. 490 Arsenal Way Suite 200 Watertown MA 02472 / US | 05 /
LAZARSKI, Kiel c/o C4 Therapeutics Inc. 490 Arsenal Way Suite 200 Watertown MA 02472 / US | [2020/39] | Representative(s) | Heller, Benjamin Henry Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2020/39] | Application number, filing date | 18878359.1 | 16.11.2018 | [2020/39] | WO2018US61573 | Priority number, date | US201762587303P | 16.11.2017 Original published format: US 201762587303 P | [2020/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2019099868 | Date: | 23.05.2019 | Language: | EN | [2019/21] | Type: | A2 Application without search report | No.: | EP3710002 | Date: | 23.09.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.05.2019 takes the place of the publication of the European patent application. | [2020/39] | Search report(s) | International search report - published on: | US | 27.06.2019 | (Supplementary) European search report - dispatched on: | EP | 07.06.2021 | Classification | IPC: | A61K31/454, A61K47/50, C07D401/14, C07D211/88, C07D403/04, C07D413/04, C07D417/04, C07D471/04 | [2021/27] | CPC: |
C07D211/88 (EP);
C07D401/04 (US);
C07D241/18 (EP);
C07D403/04 (EP,US);
C07D413/04 (EP,US);
C07D417/04 (EP);
C07D471/04 (EP)
(-)
|
| Former IPC [2020/39] | A61K31/454, A61K47/50, C07D401/14 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/39] | Title | German: | DEGRADER UND DEGRONE FÜR GEZIELTEN PROTEINABBAU | [2020/39] | English: | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | [2020/39] | French: | AGENTS DE DÉGRADATION ET DÉGRONS POUR DÉGRADATION PROTÉIQUE CIBLÉE | [2020/39] | Entry into regional phase | 05.06.2020 | National basic fee paid | 05.06.2020 | Search fee paid | 05.06.2020 | Designation fee(s) paid | 05.06.2020 | Examination fee paid | Examination procedure | 05.06.2020 | Examination requested [2020/39] | 04.01.2022 | Amendment by applicant (claims and/or description) | 16.03.2023 | Despatch of a communication from the examining division (Time limit: M06) | 26.09.2023 | Reply to a communication from the examining division | 04.04.2024 | Despatch of a communication from the examining division (Time limit: M06) | 25.09.2024 | Reply to a communication from the examining division | 12.08.2025 | Despatch of a communication from the examining division (Time limit: M04) | 18.11.2025 | Reply to a communication from the examining division | Fees paid | Renewal fee | 13.11.2020 | Renewal fee patent year 03 | 21.10.2021 | Renewal fee patent year 04 | 13.10.2022 | Renewal fee patent year 05 | 29.09.2023 | Renewal fee patent year 06 | 27.11.2024 | Renewal fee patent year 07 | 26.11.2025 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] US2763652 (SAFIR SIDNEY R et al.) [A] 6-7 * example 2; claim - * | [A] US2948723 (BICKING JOHN B et al.) [A] 6-7 * example 1; claim - * | [A] M. SAKAMOTO ET. AL.: "Solid State Photochemical Reaction of N-(alpha-beta-Unsaturated Carbonyl)-Benzoylformamides.", JOURNAL OF ORGANIC CHEMISTRY, vol. 62, no. 18, 5 September 1997 (1997-09-05), pages 6298 - 6308, XP002803003, DOI: 10.1021/jo9704974 [A] 1-5 * page 6299; figure 1 * DOI: http://dx.doi.org/10.1021/jo9704974 | [A] "Synthesis and aromatase inhibitory activity of novel 1-(4-aminophenyl)-3-azabicyclo[3.1.0] hexane and -[3.1.1] heptane-2,4-diones.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 4, 1 April 1991 (1991-04-01), pages 1329 - 1334, XP002803004, DOI: 10.1021/jm00108a013 [A] 1-5 * page 1330, Scheme IV, compound 2a * DOI: http://dx.doi.org/10.1021/jm00108a013 | International search | [Y] WO2017161119 (H LEE MOFFITT CANCER CENTER & RES INST INC et al.) [Y] 1-3 * abstract; pg 9, In 8-11; pg 53 * | [Y] US2016058872 (CREW ANDREW P et al.) [Y] 1-3 * para [0017]-[0019], [0026], Fig 2 * | [X, P] WO2017197055 (C4 THERAPEUTICS INC et al.) [X, P] 1-3, 24-26 * Entire Document * | [X, P] WO2017197046 (C4 THERAPEUTICS INC et al.) [X, P] 1-3, 24-26 * Entire Document * | [X] DATABASE PUBCHEM-CID 9 February 2007 (2007-02-09), Database accession no. 14872634 [X] 24-26 * pages 1-7. pg 2, structure * | Examination | US2016058872 | WO2017197055 | CN109641874 | WO2017161119 | by applicant | US6045501 | US6315720 | US6395754 | US6561976 | US6561977 | US6755784 | US6869399 | US6908432 | US7141018 | US7230012 | US7820697 | US7874984 | US7959566 | US8204763 | US8315886 | US8589188 | US8626531 | US8673939 | US8735428 | US8741929 | US8828427 | US9056120 | US9101621 | US9101622 | WO2017197051 | WO2017197055 | WO2017197036 | WO2017197046 | WO2017197056 | WO2015160845 | WO2016105518 | WO2016118666 | WO2016149668 | WO2016197032 | WO2016197114 | WO2017007612 | WO2017030814 | WO2017046036 | WO2017176708 | WO2017176957 | WO2017180417 | WO2018053354 | WO2018071606 | WO2018102067 | WO2018102725 | WO2018118598 | WO2018119357 | WO2018119441 | WO2018140809 | WO2017161119 | US2016058872 | MARTINIANI, R. ET AL.: "Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma", ADV HEMATO, 2012, pages 842945 | TERPOS, E. ET AL.: "Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma", ONCOTARGETS AND THERAPY, vol. 6, 2013, pages 531 | ITO, T. ET AL.: "Identification of a primary target of thalidomide teratogenicity", SCIENCE, vol. 327, 2010, pages 1345, XP055062167, DOI: 10.1126/science.1177319 DOI: http://dx.doi.org/10.1126/science.1177319 | LU, G. ET AL.: "The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins", SCIENCE, vol. 343, 2014, pages 305 - 309, XP055546390, DOI: 10.1126/science.1244917 DOI: http://dx.doi.org/10.1126/science.1244917 | KRONKE, J. ET AL.: "Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells", SCIENCE, vol. 343, 2014, pages 301 - 305 | LU ET AL., CHEM. BIOL., vol. 22, 2015, pages 755 - 763 | BONDESON ET AL.: "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target Brd4", NAT. CHEM. BIOL., vol. 11, 2015, pages 611 - 617 | GUSTAFSON ET AL.: "Catalytic in Vivo Protein Knockdown by Small-Molecule Protacs", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION IN ENGLISH, vol. 54, 2015, pages 9659 - 9662 | LAI ET AL.: "Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION IN ENGLISH, vol. 55, 2016, pages 807 - 810 | TOURE ET AL.: "Modular Protac Design for the Degradation of Oncogenic Bcr-Abl", ANGEW. CHEM. INT. ED., vol. 55, 2016, pages 1966 - 1973 | WINTER ET AL.: "Small-Molecule Protacs: New Approaches to Protein Degradation", SCIENCE, vol. 348, 2015, pages 1376 - 1381 |